Pfizer Reaffirms CV Disease Commitment With Deal For Akcea's ANGPTL3 Drug
Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.
You may also be interested in...
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.
The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.
Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.